SCHEMBL108122

SCHEMBL108122

COC(=O)c1ncccc1F

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.60
ACLY P53396 1/20 0.48
ALOX15 P16050 2/20 0.45
MAP2K1 Q02750 1/20 0.45
HTT P42858 1/20 0.45
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 4/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
PKM P14618 1/20 0.43
CTSA P10619 1/20 0.43
BRD4 O60885 1/20 0.42
KMT2A Q03164 1/20 0.41
PARP1 P09874 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
BLM P54132 1/20 0.40
AGER Q15109 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29861782 1.00 L3MBTL1 (0.60) L3MBTL1ACLYALOX15MAP2K1HTT
SCHEMBL31621400 0.84 L3MBTL1 (0.46) L3MBTL1ACLYALOX15ALDH1A1KDM4E
SCHEMBL1711562 0.81 CTNNB1 (0.42) L3MBTL1ALOX15HTTALDH1A1KDM4E
SCHEMBL18232551 0.81 L3MBTL1 (0.40) L3MBTL1ALOX15HTTALDH1A1KDM4E
SCHEMBL69177 0.81 L3MBTL1 (0.64) L3MBTL1ALOX15MAP2K1HTTALDH1A1
SCHEMBL30322596 0.81 L3MBTL1 (0.41) L3MBTL1ACLYALOX15ALDH1A1KDM4E
SCHEMBL31453471 0.81 BRD4 (0.60) L3MBTL1HTTALDH1A1KDM4ENPSR1
SCHEMBL16505732 0.81 BRD4 (0.60) L3MBTL1HTTALDH1A1KDM4ENPSR1
SCHEMBL28423158 0.81 MAPT (0.46) L3MBTL1ALDH1A1KDM4ENPSR1CTSA
SCHEMBL128711 0.79 L3MBTL1 (0.62) L3MBTL1ALOX15MAP2K1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026105052-A1 BIARYL ACID COMPOUNDS PFIZER INC. (US) 2026-05-21 WO disclosed
US-20260138982-A1 Biaryl Acid Compounds PFIZER INC (US) 2026-05-21 US disclosed
US-20260015341-A1 PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF HINOVA PHARMACEUTICALS INC (CN) 2026-01-15 US disclosed
EP-4055021-B1 HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS RIGEL PHARMACEUTICALS INC (US) 2025-10-08 EP disclosed
EP-4025568-B1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS INC (US) 2025-05-14 EP disclosed
EP-4553075-A1 PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2025-05-14 EP disclosed
EP-4025574-B1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS INC (US) 2025-05-07 EP disclosed
US-20250092057-A1 HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS RIGEL PHARMACEUTICALS, INC. 2025-03-20 US disclosed
CN-116134035-B 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors 詹森药业有限公司 2025-03-11 CN disclosed
US-20240368119-A1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIGEL PHARMACEUTICALS, INC. 2024-11-07 US disclosed
US-20090306395-A1 METALLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE SAME SAMSUNG ELECTRONICS CO., LTD., (KR) 2009-12-10 US disclosed
US-7566781-B2 Imidazopyridine compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-07-28 US disclosed
US-20080275239-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same SAMSUNG ELECTRONICS CO., LTD., (KR) 2008-11-06 US disclosed
US-20080275239-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same SAMSUNG ELECTRONICS CO., LTD., (KR) 2008-11-06 US disclosed
US-20080207905-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same SAMSUNG ELECTRONICS CO., LTD., (KR) 2008-08-28 US disclosed
US-20080207905-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same SAMSUNG ELECTRONICS CO., LTD., (KR) 2008-08-28 US disclosed
US-20080200678-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same SAMSUNG ELECTRONICS CO., LTD., (KR) 2008-08-21 US disclosed
US-20080200678-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same SAMSUNG ELECTRONICS CO., LTD., (KR) 2008-08-21 US disclosed
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide BANYU PHARMACEUTICAL., LTD. (JP) 2007-10-25 US disclosed
EP-1748048-A1 IMIDAZOPYRIDINE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide MC1R, MCHR2, MCHR1 L3MBTL1 1869/4885ACLY 4332/4885ALOX15 1331/4885
US-20260138982-A1 Biaryl Acid Compounds PIK3R1, PIK3R3, PIK3R5 L3MBTL1 3536/4885ACLY 2622/4885ALOX15 2491/4885
US-20240368119-A1 RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME RIPK1, RIPK2, RIPK3 L3MBTL1 1049/4885ACLY 3294/4885ALOX15 2648/4885
US-20080200678-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same RPS10, SCO2, NFE2L2 L3MBTL1 379/4885ACLY 1275/4885ALOX15 1120/4885
US-20260015341-A1 PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF PIK3CA, PIK3R4, PIK3R1 L3MBTL1 1917/4885ACLY 3117/4885ALOX15 2728/4885
US-20080275239-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same SCO2, NFE2L2, SOD1 L3MBTL1 1973/4885ACLY 2754/4885ALOX15 1212/4885
US-20090306395-A1 METALLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE SAME SCO2, RPS4Y1, RER1 L3MBTL1 1665/4885ACLY 2521/4885ALOX15 789/4885
US-20250092057-A1 HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS RIPK1, RIPK2, RIPK3 L3MBTL1 2180/4885ACLY 3185/4885ALOX15 2761/4885
US-20080207905-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same NOX5, PRMT5, SIRT5 L3MBTL1 1581/4885ACLY 3061/4885ALOX15 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.